AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS
申请人:Pfizer Limited
公开号:EP2155666A1
公开(公告)日:2010-02-24
[EN] AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS<br/>[FR] DÉRIVÉS D'AZÉTIDINE ET LEUR UTILISATION COMME ANTAGONISTES DES PROSTAGLANDINES E2
申请人:PFIZER LTD
公开号:WO2008139287A1
公开(公告)日:2008-11-20
[EN] The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in the treatment of endometriosis and/or uterine fibroids (leiomyomata) and to intermediates useful in their synthesis and to compositions containing them. [FR] La présente invention concerne une classe d'azétidines antagonistes des EP-2 de formule générale (I) où les variables et groupes substituants sont comme définis dans la description, et concerne en particulier les composés antagonistes des EP-2, leur utilisation en médecine, en particulier dans le traitement de l'endométriose et/ou des fibromes utérins (léiomyomatose) et les intermédiaires utiles dans leur synthèse et les compositions les contenant.
WO2022272062A1
申请人:——
公开号:WO2022272062A1
公开(公告)日:2022-12-29
Azetidines
申请人:Dack Kevin Neil
公开号:US20080280877A1
公开(公告)日:2008-11-13
The invention relates to EP2 antagonist azetidines of formula (I)
wherein Ar, R
1
, X, and Z are as defined herein, to their use in medicine, particularly in the treatment of endometriosis and/or uterine fibroids, to intermediates useful in their synthesis, and to compositions containing them.